Last updated: February 13, 2026
Overview
NDC 00781-2335 refers to Nivolumab (Opdivo), an immune checkpoint inhibitor used primarily to treat several cancers, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and others. It was approved by the FDA in 2015.
Market Size and Demand
The global oncology drug market exceeds $150 billion annually, with PD-1 inhibitors like nivolumab constituting a significant share. Nivolumab's annual sales reached approximately $9.6 billion in 2022, according to IQVIA data. Growth driven by expanding indications and approved combination therapies.
Key Market Drivers
- Expanding indications: Approved for multiple cancers including lung, melanoma, bladder, and head and neck squamous cell carcinoma.
- Combination therapies: Approved with other agents such as ipilimumab and chemotherapy, broadening its use.
- Market penetration: High adoption rates in North America, Europe, and rising use in Asian markets.
Competitive Landscape
- Primary competitors: Pembrolizumab (Keytruda), atezolizumab (Tecentriq), durvalumab (Imfinzi).
- Market share: Pembrolizumab leads with approximately 45% of the PD-1/PD-L1 class, followed by nivolumab at ~30% as of 2022.
- Differentiators: Nivolumab's efficacy, expanded indications, and established combination protocols.
Pricing Landscape
- US list price: Approximately $5,000 per 40 mg vial, varying depending on dosing schedule and indication.
- Cost per treatment cycle: Typically ranges from $100,000 to $150,000, based on dosing regimen and patient weight.
- Reimbursement: Covered widely by major insurers; however, out-of-pocket costs vary.
Price Trends and Projections
- Historical trend: Slight decrease in per-unit price over the past three years, driven by competition and biosimilar developments.
- Future projections: Prices may decline 10-15% over the next 3-5 years due to biosimilar entry, increased market competition, and value-based pricing initiatives.
- Regulatory impacts: Potential for price adjustments driven by new indications, payer negotiations, or policy reforms targeting high-cost biologics.
Regulatory and Policy Influences
- Patent exclusivity for nivolumab is expected to extend into 2030, but biosimilar development is ongoing.
- In markets like the EU, biosimilar approval pathways could influence pricing by 2025, with some biosimilars expected to enter the market at prices 20-30% lower than originator products.
- US policies aiming to reduce drug costs focus on negotiating drug prices and promoting biosimilar uptake.
Market Risks
- Patent litigation: Ongoing legal disputes can influence market exclusivity.
- Regulatory changes: Implementation of value-based payment models could pressure price reductions.
- Patent cliffs: Patent expiration timelines may accelerate biosimilar entry.
Key Data Table
| Factor |
Current Status |
Projections (Next 3-5 Years) |
| US list price (per 40 mg vial) |
~$5,000 |
Slight decline (~10%) |
| Annual global sales |
~$9.6 billion |
Minor growth expected due to new indications |
| Biosimilar approval |
Pending |
Entering market by 2024-2025 |
| Market share (PD-1 class) |
30% |
Stable or slightly declining with biosimilar entry |
Summary
Nivolumab remains a dominant PD-1 inhibitor with a robust market presence. Pricing is expected to decrease gradually due to biosimilar competition and market forces. Revenue growth will hinge on expanding indications and market penetration.
Key Takeaways
- Nivolumab (NDC 00781-2335) is among the leading immuno-oncology drugs with $9.6 billion in 2022 global sales.
- The drug’s price per treatment cycle remains high, approximately $100,000-$150,000, with slight downward pressure likely in coming years.
- Biosimilar development and approval will be pivotal, potentially reducing prices by 20-30% upon market entry.
- Market growth depends on expanding use in new indications and geographic expansion, especially in Asia.
- Regulatory policies and patent schedules critically influence future pricing and market dynamics.
FAQs
1. When do biosimilars for nivolumab likely enter the market?
Biosimilars are expected to receive approval around 2024-2025, following patent expiration scheduled into 2030.
2. How does nivolumab pricing compare globally?
Prices vary widely; US prices are among the highest, linked to payer reimbursement policies, while European and Asian markets see more negotiated or lower prices.
3. What are the primary factors influencing nivolumab's market share?
Indication approvals, clinical efficacy, competition from pembrolizumab, and biosimilar availability.
4. Will insurance coverage sustain high prices?
Reimbursement depends on clinical value, negotiations, and policy shifts toward cost containment.
5. How might new indications influence pricing?
New approved indications generally support maintained or increased pricing; however, payers may seek discounts.
Sources:
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] U.S. FDA, "Nivolumab (Opdivo) Approval Announcements," 2015-2022.
[3] EvaluatePharma, "Global Oncology Market Report," 2022.
[4] FDA, "Biosimilar Guidance and Approvals," 2023.
